Glenmark Pharmaceuticals Limited — Q3 FY26
Glenmark delivered a strong Q3 FY26 with consolidated revenue of INR 3,960 crore, up 15.1% YoY, driven by broad-based growth across markets and currency tailwinds.
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY26
India business Q3 run-rate of INR 1,150-1,200 crore
Management expects India formulation sales to return to INR 1,150-1,200 crore per quarter from Q3 FY26, with FY27 revenue exceeding INR 4,800 crore.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q2 FY26
EBITDA margin target of 23% moving to 25%+
EBITDA margin to trend towards 23% immediately and strengthen to 25%+ over time, driven by discontinuation of pre-collections and operating leverage.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1